Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

NVIDIA

A Company to Watch in the Broader Technology Sector and One Making Big Inroads in Women's Health.

Top Stock Picks for Week of November 16, 2020

Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.

Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio

Avnet

MACOM Technology Solutions Holdings

Office Depot

Top Ranked Growth Stocks to Buy for November 16th

Bull of the Day: Hologic (HOLX)

Logitech

QuidelOrtho Corp

Hologic (HOLX), Logitech (LOGI) and Quidel (QDEL) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Buy These 3 Momentum Anomaly Stocks to Maximize Your Returns

Hologic has had a stellar 2020 on the back of servicing enormous global Covid-19 testing volumes, and contract manufacturing agreements have just been extended to 2021. Management has updated guidance for 2021, where Covid testing revenues will widen the capital allocation potential into their molecular diagnosis segment.

Hologic Emerges A Winner From Covid-19 Exposure

Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.

Hologic (HOLX) is an Incredible Growth Stock: 3 Reasons Why

Hologic Inc.'s (NASDAQ:HOLX) sales skyrocketed to $1.2 billion in the company's fiscal fourth quarter, driven by demand for the company's Covid-19 tests. Revenue for the Marlborough, Massachusetts-based company were up nearly 56% in the quarter compared to the same period a year earlier.

Hologic Quarterly Sales Climb 56% on Demand for Covid Testing

Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q4 2020 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 69.67% and 7.72%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Tops Q4 Earnings and Revenue Estimates

Shares of Hologic Inc. rose more than 4% in the extended session Wednesday after the medical technology company beat Wall Street expectations for its fiscal fourth quarter and called for continued "strong financial performance" in the current quarter thanks in part to its COVID-19 test business. Hologic said it earned $495 million, or $1.88 a share, contrasting with a loss of 46 cents a share in the year-ago period.

Hologic stock higher after company reports 'strong' sales of COVID-19 tests

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020

Medical technology firm Hologic reports earnings on Wednesday, Nov. 4. The Massachusetts-based firm currently sits in a buy zone.

Buy Candidate Hologic Reports Earnings Wednesday

Hologic (HOLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Hologic (HOLX)

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #COVID19--Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity

Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity

Despite almost a 145% rise in the stock price of Hologic, since the March lows of this year, at the current price of around $70 per share, we believe HOLX stock has more room for growth. Hologic is best known for its medical devices for diagnostics, surgery, and medical imaging, and HOLX stock.

Hologic Stock Is Up 145% Off The Recent Bottom But The Rally May Continue

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the fourth quarter of fiscal 2020 amid the coronavirus-led economic doldrums.

Can Diagnostics Aid Hologic (HOLX) Q4 Sales Amid Coronavirus?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of Hologic, Inc. (NASDAQ:HOLX).

Were Hedge Funds Right About Piling Into Hologic, Inc. (HOLX)?

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #COVID19--Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe

Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe

Abbott Labs

Quest Diagnostics

Labcorp Holdings Inc

Our indicative theme of Covid-19 Testing Stocks, which includes medical devices and diagnostic companies that are involved in Covid-19 testing - is up by about 69% year-to-date, significantly outperforming the S&P 500 which is up by about 8% over the same period. Testing is viewed as key to.

Covid Testing Stocks To Watch As The Holidays Near

Hologic stock gained 15% over the last month to levels of around $69 currently. But will the company’s stock see higher levels over the coming weeks, or is a decline in the stock imminent?

Hologic Stock Is Up 15% In A Month, What Are The Chances It’ll Fall From Here?

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2020 on Wednesday, November 4, 2020

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2020 on Wednesday, November 4, 2020

The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.

FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #COVID19--FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals

FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling

News for Hologic Stock (HOLX)